Perioperative medicine is emerging as a transformative, comprehensive, system-wide approach to patient care before, during, and after surgery – that reduces complication rates and hospital days, provides better health outcomes, and improves health system performance, according to a special article in the Online First edition of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists (ASA).

Gallbladder cancer (GBC) is an extremely aggressive biliary tract malignancy characterized by silent early progression, late-stage diagnosis and poor prognosis. It is one of the most lethal gastrointestinal cancers, with a five-year survival rate often below 10%, partly because only about 10-20% of patients are eligible for curative surgical resection at diagnosis. 

A key focus of molecular research is whether Actionable Genomic Alterations (AGAs) – specific DNA changes in cancer cells – independently impact survival beyond established factors like stage and treatment.

A new study by researchers at Boston University Chobanian & Avedisian School of Medicine has found that patients with gallbladder cancer who had certain documented gene changes in their tumor had a higher risk of death, even when we compared them with similar patients based on age, sex, race/ethnicity, cancer stage, surgery and chemotherapy.